Very powerful in the few patients that can tolerate more than 5 to 10mg per day with the restriction being the rapid elevation of liver enzymes AND the diarrhea issue. The remaining issues besides why pay $295K for patients on only 5 to 10mg are the increased risk of developing atrial fibrillation secondary to those elevated liver enzymes, and what about those increases in fatty infiltration of the small intestine? Halt_the_ranger with his vast knowledge has not being able to speak yet:))))))) t
Please take a Rosetta Stone course on how to speak English, or change your name to Senddilxxo(yourself) back to the Antarctic. t
One out of three days that Vicl did a little bit better than ISIS and you have to be a morning rooster about it. Of course you left you that ISIS went up over three points in 48 hrs and that this may relate to profit taking.. VICL is a junk stock, 75% below it's yearly high. It faces a tremendous amount of competition and their products are more dangerous than ISIS IMO. They could cause patients to develop Gillian-Barre Syndrome. Worst yet in their lastest fiasco they may not work at all and may do way worse than placebo. Of course the whole company is guided by arguably the worse CEO in the business last year. Keep on receiving instructions from your biotech equivalent of Mr. Putin and let's continue to talk as the year progresses.........as long as you have the courage to keep on appearing on website that is for ISIS not VICL. I suspect you will because you have Mr. Putin-like training. Looking forward to doing business with you Mr. Putin-like miniature. t
Lpath reports interim data from Phase 2a study for anti-cancer drug, ASONEP; based on encouraging progression-free survival data, co extends the study to a second cohort and considers additional proof-of-concept studies (3.71)
•Co reported interim results in a Phase 2a single-arm, open-label trial where ASONEP is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor/everolimus), with a maximum of three failed treatments in all.
•This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.
You have to be the dumbest liar out there. According to your posts over the last five years you would never own ISIS no matter what.......and to buy it and hold it until 50.....like ya. You keep saying you are loading up on vicl and you live in mom's basement without a job....that's another lie. t
Differential effects of Akt1 signaling on short- versus long-term consequences of myocardial infarction and reperfusion injury
Laboratory Investigation, 07/23/2014 Clinical Article
Ma L, et al. – The data suggest that better understanding of the Akt1/GSK–3 pathway may provide insights for better therapeutic strategies in post–MI tissues.
Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways
Head & Neck, 07/23/2014 Clinical Article
Axelrod MJ, et al. – The authors aim to investigate that synergistic apoptosis in head and neck squamous cell carcinoma (HNSCC) cells by co–inhibition of insulin–like growth factor–1 receptor signaling and compensatory signaling pathways. Combined IGF1R/HER family and IGF1R/Src family inhibition may have therapeutic potential in HNSCC. AKT may be a node of convergence between IGF1R signaling and pathways that compensate for IGF1R inhibition.
Glad I sold my VICL and put it all in INO about three months ago. Predict VICL will be $1.80 by Jan 1st, ISIS will be $75. Wondering when VICL will pass ISIS in price..........maybe maybe by the year 3001 when the ice age comes back. In the meantime, I'm going to by a lot of other biotechs besides VICL. t
The company can hold out without a partner and still advance their drugs in the lab the higher the price will be when they do partner their drugs. This is a three investment IMO. Don't let people dissuade you from you goals. There has been no bad news, and recent news was relatively good. Time and patience is what is needed. Will continue to follow this stock and give updates. Plan a calling their IR soon. Some dumbos who don't know anything and say the stock sucks without any validation are zzzzzz. t
Hey A1, worth about maybe 15 to 20 on a lotto pick. Average dose being used is 5 to 10mg when the FDA thought it would be about 40mg. Paying $239K for this drug.....I'd really feel guilty about taking the health care system for that much for so little. t
VICL in trouble if it can't keep up with the other DNA vaccine companies. Still down over 75% from highs on the year. Good thing, like sand-bagging in bowling. Soon the high for the year will be less than $1.30 and so in about a year you will be able to use your Putin strategy about talking how VICL is making new highs every week as it inches toward a buck forty. You should really look for a job in some communist goverment where you can spew out your BS to the people. t
The value goes up as you go through the evaluation process. Why give the drug away? Things IMO are going as expected. Going after CA as a disease has the highest risk of any biotech undertaking, save maybe Alzhemier disease. The stock is extremely cheap here. Three year target of $15 which is easily obtainable with success in the lab. t
Skeletal muscle homeostasis in Duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategy
Frontiers in Neurology, 07/17/2014 Review Article
De Palma C, et al. – The aim of this review is to describe and discuss the clinical relevance of the recent advances dissecting autophagy and its signalling pathway in Duchenne muscular dystrophy (DMD). The study suggest that at molecular levels, the Akt axis is one of the key disregulated pathways, although the molecular events are not completely understood.
Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease
Journal of the American Society of Nephrology, 07/16/2014 Clinical Article
Hanatani S et al. – In this study, authors utilized a skeletal muscle–specific, inducible Akt1 transgenic (Akt1 TG) experimental model that promotes the growth of functional skeletal muscle independent of exercise to investigate the effects of muscle growth on kidney diseases. However, the data support the concept that loss of muscle mass during kidney disease can contribute to renal failure, and maintaining muscle mass may improve clinical outcome.
You're trying too hard. If the stock tanks and the company goes out of business.....then come back and kick everyone's #$%$. But the reality is this is how biotechs are. VRTX started back in 1989 as did SRPT, known as AVII. This company has huge risk, but also huge potential. Not an investment for everyone, and it appears especially not an investment for you. t
You are on the ISIS board which is a forum for ISIS and you are telling dutiful people here to scram......that is a reflection of your psychosis. Talk to your doctor about Lutuda.....a Zyprexa without the weight gain. Got to look out for even people like you. t
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin(mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma
Cancer Treatment Reviews, 07/14/2014 Review Article Clinical Trial Below
Beck JT, et al. – This review will discuss therole of the PI3K/AKT/mTOR pathwayin cancer and how the discovery ofgenetic alterations in this pathway in patients with squamous cell lung carcinoma can inform the development of targeted therapies for this disease. An overview of ongoing clinical trials investigating PI3K/AKT/mTOR pathway inhibitorsinsquamous cell lung carcinoma will also be included.